Paul Buckman
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 5, 2026
NeuroOne Reports Strong Q4 Sales, New $4.5M Order. NeuroOne Medical Technologies said its Q4 sales were about $3.8 million, up 38% from last year. The company also added a $4.5 million purchase order in September and expects FY26 sales of roughly $10.5 million, a 15.6% increase year‑over‑year. These results come as the share price sits near its 12‑touch support level of $1.63 and an RSI of 45.8.
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 28, 2026
Solana Company Faces Analyst Target Shift and Rumor Collapse. Solana Company (HSDT) saw mixed analyst activity. Morgan Stanley cut its target to $6, while B. Riley lifted its to $4. Rumors of an Alpenglow mainnet launch fell apart after developers said 'No Alpenrush'. An options market analysis suggested a potential spike. The company also highlighted that its key metric is SOL per share.
Transaction History
| SI | ▲ Buy | Grant | 1,275 | $25K | 10/5/2026 | View on chart |
| SI | ▲ Buy | Grant | 5,046 | $0 | 6/26/2026 | View on chart |
| NMTC | ▲ Buy | Grant | 41,929 | $0 | 4/3/2026 | View on chart |
| HSDT | ▲ Buy | Grant | 2,180 | $0 | 3/31/2026 | View on chart |
| SI | ▼ Sell | Tax Withholding | 3,292 | $48K | 3/13/2026 | View on chart |
| SI | ▼ Sell | Tax Withholding | 3,714 | $55K | 3/13/2026 | View on chart |
| SI | ▲ Buy | Option Exercise | 19,401 | $48K | 3/13/2026 | View on chart |
| SI | ▲ Buy | Option Exercise | 26,205 | $55K | 3/13/2026 | View on chart |
| SI | ▼ Sell | Other | 6,198 | — | 8/1/2025 | View on chart |
| SI | ▲ Buy | Grant | 7,666 | $0 | 8/1/2025 | View on chart |
| NMTC | ▲ Buy | Grant | 27,778 | $0 | 2/14/2025 | View on chart |
| NMTC | ▲ Buy | Grant | 27,778 | $22K | 8/1/2024 | View on chart |
| HSDT | ▲ Buy | Grant | 83,054 | $0 | 5/24/2023 | View on chart |
| NMTC | ▲ Buy | Grant | 20,576 | $0 | 3/16/2023 | View on chart |
| NMTC | ▲ Buy | Grant | 29,240 | $0 | 5/31/2022 | View on chart |
| HSDT | ▲ Buy | Grant | 6,049 | $0 | 5/23/2022 | View on chart |
| HSDT | ▲ Buy | Grant | 721 | $0 | 9/10/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 12, 2026
Shoulder Innovations Q2 2026 earnings and BTIG target raise
Shoulder Innovations held its Q2 2026 earnings conference call, where management discussed the quarter’s results. BTIG analyst kept its rating on the stock and increased the price target to $27. The new target is above the current average analyst estimate of $26.25 and above the 52‑week high of $24.59.
Shoulder Innovations Q2 2026 earnings and BTIG target raise. Shoulder Innovations held its Q2 2026 earnings conference call, where management discussed the quarter’s results. BTIG analyst kept its rating on the stock and increased the price target to $27. The new target is above the current average analyst estimate of $26.25 and above the 52‑week high of $24.59.